SAGA Diagnostics has entered service agreements with the international pharmaceutical company Servier, based in Paris, France.

“These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects,” says Lao Saal, CEO of SAGA Diagnostics.

Three preclinical/clinical studies

The collaboration will be covering a total of three preclinical/clinical studies and is scheduled to run for approximately two years. In the course of these projects, SAGA Diagnostics will be developing assays and performing liquid biopsy tests on patients from multiple Servier clinical studies using the SAGAsafe technology (formerly known as IBSAFE) to identify and quantify circulating tumor DNA (ctDNA).

The analyses will be run in the SAGA Diagnostics central laboratory in Lund, Sweden.

“We have been impressed by the service and ultra-sensitivity performance of SAGAsafe’s analyses and are looking forward to continue working together. Involving the SAGAsafe technology in these studies means that Servier will now be able to monitor effects at an earlier stage ensuring that we do not miss out on any insights,” says Brian Lockhart, Director of CentEx-Biotechnology, Servier.